NewLink Genetics Corporation (NASDAQ:NLNK) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Several other analysts have also recently commented on the company. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corporation and gave the stock a “buy” rating in a report on Sunday, June 4th. Robert W. Baird upgraded NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $8.00 to $22.00 in a report on Friday, September 8th. Zacks Investment Research cut NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Jefferies Group LLC restated a “hold” rating and set a $7.00 target price on shares of NewLink Genetics Corporation in a report on Friday, July 14th. Finally, Stifel Nicolaus upped their price target on NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $24.17.

Shares of NewLink Genetics Corporation (NASDAQ:NLNK) traded down 8.46% during midday trading on Wednesday, reaching $13.74. 2,754,713 shares of the company’s stock traded hands. The firm’s market capitalization is $404.24 million. NewLink Genetics Corporation has a 52-week low of $5.90 and a 52-week high of $25.17. The stock’s 50 day moving average price is $8.00 and its 200 day moving average price is $12.84.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its earnings results on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.21. The company had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. On average, equities research analysts anticipate that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/14/newlink-genetics-corporation-nlnk-lowered-to-sell-at-valuengine.html.

Several institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of NewLink Genetics Corporation by 5.6% during the first quarter. Vanguard Group Inc. now owns 959,883 shares of the biotechnology company’s stock valued at $23,134,000 after acquiring an additional 51,013 shares during the period. Columbus Circle Investors lifted its stake in shares of NewLink Genetics Corporation by 72.5% during the second quarter. Columbus Circle Investors now owns 591,765 shares of the biotechnology company’s stock valued at $4,349,000 after acquiring an additional 248,724 shares during the period. State Street Corp lifted its stake in shares of NewLink Genetics Corporation by 1.2% during the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after acquiring an additional 4,630 shares during the period. Northern Trust Corp lifted its stake in shares of NewLink Genetics Corporation by 4.0% during the second quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock valued at $2,195,000 after acquiring an additional 11,532 shares during the period. Finally, Driehaus Capital Management LLC acquired a new position in shares of NewLink Genetics Corporation during the first quarter valued at $5,127,000. 54.78% of the stock is currently owned by institutional investors and hedge funds.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.